Genetics Institute

Reaches agreement-in-principle with European erythropoietin licensee Boehringer Mannheim to settle a contract dispute related to the manufacture of EPO for Boehringer during 1989, valued at$13 mil. Boehringer has agreed to accept a portion of the EPO it had previously disputed, and Genetics Institute has agreed to replace in fiscal 1991 some of the disputed material with product manufactured via a different process. Last month, Boehringer Mannheim received a favorable recommendation for EPO marketing in Europe from the EC's Committee for Proprietary Medicinal Products. The company says it expects to launch EPO within the next several months.